Combining EGFR and mTOR Blockade for the Treatment of Epithelioid Sarcoma

Abstract

EGFR and mTOR signaling pathways are deregulated in ES. Preclinical ES model-derived insights suggest that combined inhibition of these targets might be beneficial, supporting evaluations in clinical trials.